Drug Database
SC

SC-001 (SP009 / SC001)

✓ Approved

Declion Pharmaceuticals · · Polypeptide

What is SC-001?

SC-001 is a polypeptide developed by Declion Pharmaceuticals. It is approved for therapeutic indications via injectable (others) or intradermal injection.

Drug Profile

Brand NamesSP009, SC001
CompanyDeclion Pharmaceuticals
Drug ClassPolypeptide
RouteInjectable (Others), Intradermal Injection
StatusApproved
Sources: ClinicalTrials.gov, Declion Pharmaceuticals

Mechanism of Action

Molecular Targets

SC-001 acts on 1 molecular target:

()
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

SC-001 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresBotulinum toxin injection✓ Approved

Related Research Articles

PubMedbioRxiv : the preprint server for biology2026-07-17

Fibroblasts impair muscle stem cell self-renewal via excessive fibronectin deposition in viscoelastic hydrogel co-cultures.

Chang Tze-Ling TL, Vallery Tenaya K TK, Zlatkov Thea S TS, Olwin Bradley B BB et al.

Muscle satellite cells (SCs) regenerate skeletal muscle, but their regenerative capacity declines with age, in part due to extracellular matrix (ECM) remodeling and aberrant fibroblast activation within the SC niche. In regenerating young mouse muscle, fibronectin remodeling is transient, whereas in aged mouse muscle, fibronectin remodeling is prolonged and disorganized. Fibroblasts in aged mice are activated, increasing fibronectin deposition and expressing elevated α-smooth muscle actin (αSMA), which negatively influence SC fate. We develop a viscoelastic hydrogel co-encapsulation system, enabling three-dimensional co-culture of intact myofibers with primary fibroblasts. Using this 3D co-culture system, we show that fibroblasts from young mice support SC quiescence and self-renewal, whereas fibroblasts from aged mice aberrantly activate SCs and promote their differentiation on myofibers isolated from either young or aged mice. Knocking down fibronectin ( Fn1 ) in fibroblasts from aged mice partially restores SC function, promoting quiescence and limiting differentiation. Using a novel 3D hydrogel co-culture system, we demonstrate that fibroblast-deposited fibronectin is a key age-associated regulator negatively affecting SC fate within the SC niche of aged mice.

PMID 42465277
Read full article →
PubMedIntensive care medicine experimental2026-07-17

Source control within 12 h attenuates lung injury and systemic bacterial burden in a rat model of polymicrobial abdominal sepsis (cecal ligation and puncture).

Martinez Maria Luisa ML, Torrents Eva E, Camprubí-Rimblas Marta M, Bringué Josep J et al.

Early and adequate source control (SC) is a cornerstone of sepsis management, yet experimental data linking delays in SC to bacterial dissemination and remote organ injury remain limited. We aimed to determine how the timing of surgical SC after polymicrobial abdominal sepsis influences bacterial burden, host inflammatory response, and lung injury. Hemodynamic recovery was assessed as a secondary outcome, and survival as an exploratory outcome. Adult Wistar rats underwent cecal ligation and puncture (CLP) and received standardized fluid resuscitation and meropenem. Surgical SC (cecal resection plus peritoneal lavage) was performed at 6, 12, 18 or 24 h after CLP, or not performed, and outcomes were assessed at 72 h (hemodynamics, lactate, bacterial counts in blood/peritoneal lavage/bronchoalveolar lavage, systemic and pulmonary cytokines, bronchoalveolar lavage cellularity and histology). Surgical SC within 6-12 h was associated with lower bacterial burden across blood, peritoneal lavage, and bronchoalveolar lavage, together with attenuation of systemic and pulmonary inflammatory mediators and reduced lung injury. These biological effects were accompanied by improved mean arterial pressure, lower lactate, and preservation of body weight. Survival analysis suggested a numerically time-dependent pattern according to SC timing; however, these data were exploratory and the study was not powered to detect mortality differences. In this clinically relevant CLP rat model, earlier surgical SC (≤ 12 h) was associated with lower bacterial burden, attenuation of systemic and pulmonary inflammation, reduced sepsis-associated lung injury, and improved physiological recovery. These findings reinforce the importance of timely source control in abdominal sepsis and provide experimental support for avoiding unnecessary delay.

PMID 42467176
Read full article →
PubMedMolecular and cellular pediatrics2026-07-17

Subcutaneous infliximab as a maintenance option in pediatric IBD: a real-world cohort including younger and lower-weight children.

Ridder Neele N, Overberg Johanna J, Kalveram Laura L, Pudasaini Samipa S et al.

Subcutaneous infliximab (SC-IFX) offers an alternative to intravenous infliximab (IV-IFX) in adults with inflammatory bowel disease (IBD), but evidence in children is scarce. This study reports treatment persistence, tolerability, and pharmacokinetics in a real-world pediatric IBD cohort following transition from IV-IFX. We conducted a single center retrospective study including all pediatric IBD patients transitioned from IV-IFX to SC-IFX (120 mg every other week) at our institution between November 2023 and April 2025. Clinical disease activity scores, inflammatory markers, IFX serum concentrations, and anti-IFX antibodies (AIA) were assessed at baseline and during follow-up. The primary outcome was treatment persistence. Secondary outcomes included disease activity, pharmacokinetics, immunogenicity and tolerability. Twenty patients (median age 14.5 years; range 5-17), including six children < 12 years and five weighing < 40 kg, were included. After a median observation period of 44 weeks (IQR 26-60), 16/20 patients (80%) remained on SC-IFX, with no significant difference between Crohn's disease and ulcerative colitis. In a subgroup of four patients who received SC-IFX as a third dose following two intravenous induction doses, 3/4 (75%) maintained treatment over a median observation period of 60 weeks (range 16-64 weeks) and remained in clinical remission during follow-up. IFX serum concentrations increased after switching (median 11.8 µg/mL pre-switch vs. ≥24 µg/mL at follow-up), with most follow-up measurements reaching the assay ceiling. Concentrations were descriptively comparable between weight groups. All patients with detectable AIA prior to switching became antibody-negative during SC-IFX therapy, and no de novo antibodies were observed. Two patients discontinued therapy due to worsening of pre-existing paradoxical psoriasis. No other adverse events were documented. SC-IFX showed high persistence, stable inflammatory markers and good tolerability in this pediatric cohort, including younger and lower-weight children. SC-IFX appears to be a feasible maintenance option in selected pediatric patients, including early use after induction. Prospective studies are warranted to define pediatric-specific pharmacokinetic targets and individualized dosing strategies.

PMID 42463592
Read full article →
PubMedbioRxiv : the preprint server for biology2026-07-17

Frontal Eye Field Leads a Distributed Oculomotor Circuit for Abstract Categorical Decisions.

Zhu Ou O, Shirhatti Vinay V, Garza Maura M, Xu Yunlong Y et al.

Flexible decisions require the brain to transform sensory evidence into abstract, task-relevant variables and then into actions. Understanding this process requires identifying how distributed neural populations represent sensory, cognitive, and motor variables, and how interareal interactions mediate transformations between them. We simultaneously recorded population activity in frontal eye field (FEF), lateral intraparietal area (LIP) and superior colliculus (SC) while monkeys performed a flexible yet urgent visual motion-categorization task. Within this network, FEF first encoded abstract categories, followed by SC and then LIP. LIP showed the earliest encoding of visual stimulus features, but a later encoding of upcoming saccades. Single-trial analyses revealed directed information flow from FEF to LIP populations for category-and choice-related signals. Reversible FEF inactivation impaired categorization and saccadic choice, causally implicating FEF in category-guided action. These findings reveal a differentiated FEF-LIP-SC circuit for transforming sensory evidence into abstract categorical decisions and the actions used to report them.

PMID 42465361
Read full article →
PubMedNeurobiology of disease2026-07-17

Dysregulation of the Schwann cell GABAergic system and Aβ-fibers conduction abnormalities in the sciatic nerve of the mdx mouse model of Duchenne muscular dystrophy.

Di Nuzzo Silvia S, Mastrostefano Francesca F, Soligo Marzia M, Mohamed Tasnim T et al.

Duchenne muscular dystrophy (DMD), a lethal X-linked disorder caused by loss of the full-length dystrophin Dp427, is characterized by progressive skeletal muscle degeneration, although increasing evidence indicates a broader neuromuscular dysfunction. Here, we identify impaired Schwann cell (SC) homeostasis in the sciatic nerve of dystrophic mdx mice. Integrated molecular, immunofluorescence, ultrastructural, and electrophysiological analyses demonstrate that sciatic nerves from 6 to 7-week-old mdx mice exhibit downregulation of key myelin proteins (MBP, P0, PMP22), compared with age-matched wild type mice. Despite preserved SC dystrophin isoforms (Dp116 and Dp71), core components of the dystrophin-associated glycoprotein complex (DGC), namely α- and β-dystroglycan and dystrobrevin, are significantly reduced. Concomitant activation of matrix metalloproteinases (MMP)-2 and MMP-9 is consistent with enhanced proteolytic processing and DGC destabilization. These alterations are accompanied by reduced mRNA and protein expression of GABA-A and GABA-B receptors and the GABA-synthesizing enzymes GAD65 and GAD67, indicating perturbed autocrine/paracrine GABAergic signaling at the SC-axon interface, further supported by altered neuregulin-1/ErbB2 signaling. Furthermore, sensory Aβ-fibers from mdx mice exhibit mild hypoexcitability, altered refractoriness, and impaired tolerance to high-frequency stimulation, consistent with impaired myelin integrity and diminished electrical insulation, confirmed by ultrastructural evidence of focal myelin abnormalities affecting a subset of nerve fibers. Notably, none of the parameters examined in 10-day-old mdx mice showed detectable alterations, suggesting that sciatic nerve abnormalities become evident after the onset of overt muscle degeneration. Altogether, these findings identify the sciatic nerve as a previously underappreciated site of disease-associated alterations in DMD and a potential target for future therapeutic investigations.

PMID 42462892
Read full article →
PubMedJournal of nephrology2026-07-17

Prevalence of protein-energy wasting among non-dialytic and dialytic chronic kidney disease patients in Africa: a systematic review and meta-analysis.

Adejumo Oluseyi Ademola OA, Oyedepo Dapo Suday DS, Edeki Imuetinyan Rashida IR, Busari Kudirat Abimbola KA et al.

Protein-energy wasting (PEW) is a frequent and prognostically adverse complication of chronic kidney disease (CKD). Despite its clinical importance, African populations have been underrepresented in prior systematic reviews. This study aimed to estimate the pooled prevalence of PEW among patients with CKD in Africa. PubMed, AJOL, and EMBASE were systematically searched for relevant studies published between 1980 and 2025. Meta-analytic techniques were used to estimate the pooled prevalence of PEW among African CKD populations. The study protocol was registered on PROSPERO (CRD420251032894). Twenty-five articles comprising 2822 participants across 14 African countries met the inclusion criteria. The mean age of the participants was 49.7 ± 5.2 years. Thirteen studies (52.0%) were from North Africa, 19 studies (76.0%) had high methodological quality, and 17 studies (68.0%) used Subjective Global Assessment (SGA) for PEW assessment. The overall pooled prevalence of PEW among patients with CKD was 47.0% (95% confidence interval: 39.0%-56.0%; n = 25 studies; I2 = 95.5%, P < .001). The prevalence of PEW was significantly higher in the haemodialysis patients compared with non-dialysis CKD patients (52.0% vs 34.0%; P < .001). The pooled prevalence of PEW in studies that used the International Society of Renal Nutrition and Metabolism criteria was 32.0%; Malnutrition Inflammatory Score was 49.0%, SGA was 42.0%; and SGA adaptation was 76.0%. There was a significant difference in the pooled PEW prevalence across diagnostic criteria (P < .001) and African regions (P < .001). PEW is highly prevalent among African patients with CKD. Region-specific guidelines and multidisciplinary nutritional interventions are urgently needed to address this burden.

PMID 42467426
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about SC-001